References
- Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(11): 1935–9. doi: 10.1111/jth.12672.
- Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: Huge impact of a tiny difference. Res Pract Thromb Haemost 2020; 4(3): 377–385. doi: 10.1002/rth2.12314.
- Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046. Erratum in: Haemophilia. 2021 Jul;27(4):699. doi: 10.1111/hae.14308.
- Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677–1686. doi: 10.2147/PPA.S139851.
- Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018; 16(12): 2362–2374. doi: 10.1111/jth.14296.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: 14898. doi: 10.1136/bmj.l4898.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372. doi: 10.1136/BMJ.N71.
- Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.
- Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood 2019; 134(22): 1973–1982. doi: 10.1182/blood.2019001542.
- Matsushita T, Shapiro A, Abraham A, et al.; explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med 2023; 389(9): 783–794. doi: 10.1056/NEJMoa2216455.
- Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicenter, open-label, randomised, phase 3a trial. Lancet Haematol 2024; 11(12): e891–e904. doi: 10.1016/S2352-3026(24)00307-7.
- Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomised first human dose trial. J Thromb Haemost 2015; 13(5): 743–54. doi: 10.1111/jth.12864.
- GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2024. Available from gradepro.org. n.d.
- Eichler HJ, Angchaisuksiri P, Kavakli K, et al. Concizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia 2018; 25(1): 60–66. doi: 10.1111/hae.13627.
- Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: a current update. Blood Transfus 2018; 16(5): 457–461. doi: 10.2450/2018.0272-17.
- Gualtierotti R, Pasca S, Ciavarella A, et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals (Basel) 2022; 15(10): 1183. doi: 10.3390/ph15101183.
- Ali MA, Aiman W, Bajwa S, Anwer F. Comparison of drugs used for prophylaxis in hemophilia A or B with Inhibitors: A systematic review and frequentist network meta-analysis of randomised clinical trials. Blood 2024; 144 (Suppl 1): 5488. doi: 10.1182/blood-2024-211537.
- European Medicines Agency. EPAR – Alhemo (concizumab): Initial Marketing Authorisation Documents. EMA/511415/2024. Published 2024. Available from
https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo (accessed November 2025).